4,7-Di(thiophen-2-yl)-[1,2,5]thiadiazolo[3,4-c]pyridine

Catalog No. :
ACFWAN583
CAS No. :
1007128-74-6
Molecular Formula :
C13H7N3S3
Molecular Weight :
301.42

IUPAC Name:4,7-di(thiophen-2-yl)-[1,2,5]thiadiazolo[3,4-c]pyridine

4,7-Di(thiophen-2-yl)-[1,2,5]thiadiazolo[3,4-c]pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg99%$72.00Login to see priceInquiryInquiry
250mg99%$122.00Login to see priceInquiryInquiry
1g99%$329.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4,7-Di(thiophen-2-yl)-[1,2,5]thiadiazolo[3,4-c]pyridine
IUPAC Name4,7-di(thiophen-2-yl)-[1,2,5]thiadiazolo[3,4-c]pyridine
Molecular FormulaC13H7N3S3
Molecular Weight301.42
SMILESC12=NSN=C1C(C3=CC=CS3)=NC=C2C4=CC=CS4
InChI KeyVIIFSDQVOHEEHN-UHFFFAOYSA-N
Synonym4,7-bis(2-thienyl)thieno[3,4-c]pyridine;[1,2,5]Thiadiazolo[3,4-c]pyridine, 4,7-di-2-thienyl-;PT-2Th;4,7-dithienyl[1,2,5]thiadiazolo[3,4-c]pyridine;4,7-Di(thiophen-2-yl)-[1,2,5]thiadiazolo[3,4-c]pyridine
CAS No.1007128-74-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319
Precautionary Statement(s)
P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364

Synthetic Route by SureRoute

1. ACFWAN583 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACUXRB496 route compound structure diagram
    ACUXRB4966165-68-0 In Stock
  4. Then
  5. ACFWAN583 route product structure diagram
    ACFWAN5831007128-74-6
Inquiry

2. ACFWAN583 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACUXRB496 route compound structure diagram
    ACUXRB4966165-68-0 In Stock
  4. Then
  5. ACFWAN583 route product structure diagram
    ACFWAN5831007128-74-6
Inquiry

Comments (0)